Loss of high‐affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies
- 1 March 1991
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 29 (3) , 256-262
- https://doi.org/10.1002/ana.410290305
Abstract
Cholinergic replacement therapies have yielded little or no clinical improvement in Alzheimer's disease (AD). Since the number of postsynaptic muscarinic receptors remains unchanged in the cerebral cortex, the involvement of other neurotransmitter systems may account for this limited efficacy. Alternatively, there may be a defective coupling of the muscarinic receptor with its nucleotide-binding protein in AD, which would severely limit the ability of cholinergic agonists to activate intracortical second messengers. To address this possibility, we assessed the ability of the putative M1 muscarinic receptor to form high-affinity agonist-receptor complexes with guanine nucleotide regulatory proteins in postmortem frontal cortex. Agonist affinity states of the M1 muscarinic receptor were measured by carbachol/[3H]-pirenzepine competition. M1 muscarinic receptors exhibited both high (KH) and low (KL) affinities for the agonist carbachol. High-affinity agonist binding to M1 receptors in postmortem frontal cortex samples from subjects with AD was reduced, demonstrated by an increase in the KH value. Low-affinity agonist binding (KL value) was unchanged in AD and was not significantly different from the KL value for the uncoupled receptor determined in the presence of guanine nucleotides. The increase in the KH value resulted in a 70% decrease in the average KL/KH ratio for AD as compared to control samples. Choline acetyltransferase activities correlated significantly with the KL/KH ratios (r = 0.73,p < 0.001). These data suggest that the KL/KH ratio for muscarinic agonists may serve as a neurochemical marker of disease severity. The reduced ability of the M1 receptor subtype to form a high-affinity agonist state in AD may account for the failure of cholinergic replacement therapies to improve specific features of memory and cognition.Keywords
This publication has 40 references indexed in Scilit:
- Alzheimer's disease: is there a problem beyond recognition?Trends in Pharmacological Sciences, 1990
- Distribution of muscarinic receptor subtypes within architectonic subregions of the primate cerebral cortexJournal of Comparative Neurology, 1988
- Decreased levels of protein kinase C in Alzheimer brainBrain Research, 1988
- Decreased muscarinic receptor binding in cerebral cortex and hippocampus in alzheimer's diseaseLife Sciences, 1987
- Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer TypeNew England Journal of Medicine, 1986
- Neurochemical Studies of Early-Onset Alzheimer's DiseaseNew England Journal of Medicine, 1985
- Slow cholinergic excitation — a mechanism for increasing neuronal excitabilityTrends in Neurosciences, 1983
- Memory Enhancement with Oral Physostigmine in Alzheimer's DiseaseNew England Journal of Medicine, 1983
- SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASEPublished by Elsevier ,1976
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973